Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice.

Perez-Ruiz, E; Jimenez-Castro, J; Berciano-Guerrero, MA; Valdivia, J; Estalella-Mendoza, S; Toscano, F; Artacho, MRD; Garrido-Siles, M; Martinez-Bautista, MJ; Roldan, RV; Rivas-Ruiz, F; Nogales-Fernandez, E; Morales, C; Perez-Valderrama, B; De la Cruz-Merino, L; Rueda, A – 2020